Core Scientific, Inc./tx — Form 8-K
Filed August 27, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Core Scientific executed a Credit Agreement dated August 25, 2026 with JPMorgan Chase Bank as Administrative Agent and a syndicate of lenders including Morgan Stanley, Goldman Sachs, and TD Securities. The facility comprises $100M in Revolving Facility Commitments and $500M in L/C Facility Commitments (total $600M), with an initial 3-year maturity (extendable to 4 years at borrower option). Applicable margin is 1.75% for Term SOFR loans and 0.75% for ABR loans, with a 0.25% commitment fee. Use of proceeds specified as working capital and general corporate purposes.
Why this rating
Routine debt refinancing/new facility. $600M facility is ~14% of $4.3B market cap—material but not transformative. Standard commercial credit terms, no equity dilution, no operational changes disclosed.
See more from August 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.